Immunology

October16th,2020

Best of Immuno-oncology

Download DDN’s “Best of Immuno-oncology” ebook to learn more about recent research in cancer immunotherapy. This ebook includes stories about antibody approaches for treating cancer, the potential of CAR-T therapies, precision cancer immunotherapy directed by immune-profiling, and cancer neoepitope discovery.

August31st,2020By Randall C. Willis

Why cellular context is vital for genomics and transcriptomics insights (Sanger Institute)

Gosia Trynka, Group Leader at The Sanger Institute and Experimental Science Director at Open Targets, talks about the importance of cellular context for translating genomic and transcriptomic insights into actionable targets.

August25th,2020

Five Challenges in Plate Assays that Can Be Mastered by the Right Choice of Pipetting Tool

July15th,2020By Kristen Smith

CROs create COVID partnership

U.K companies seek to provide drug discovery and development services despite pandemic restrictions

July15th,2020By Mel J. Yeates

OSE brings CLEC-1 to AACRR

CLEC-1 is a new therapeutic target for immuno-oncology.

The research program focuses on developing a cancer immunotherapy targeting CLEC-1, a newly identified C-type lectin receptor, to block suppressive functions of myeloid cells and restore antitumor response to T lymphocytes. Suppressive myeloid cells have the ability to accumulate in the tumor microenvironment and deregulate the immune activation of T lymphocytes.

July15th,2020By DDN Staff

IONTAS announces collaboration

Partnership with Inotrem will seek to identify novel immunotherapy targets

July9th,2020

Webinar: Synthetic DNA Technologies Enable Fast and Responsive Antibody-based Therapeutics and Diagnostics for SARS-CoV-2

Utilizing its proprietary DNA technology to write synthetic libraries, Twist Biopharma provides end-to-end antibody discovery and optimization solutions for the biotechnology industry.

June23rd,2020By DDN Staff

A ‘Scenic’ view on cancer treatment

Scenic Biotech awarded €3.1-million from Dutch government to progress CD47/QPCTL immuno-oncology program

June23rd,2020By DDN Staff

Immune cells infiltrating tumors may play bigger cancer role than previously thought

UC San Diego researchers unravel how immune cells operate in the tissues surrounding mouse tumors, suggesting new approach for cancer therapies

June23rd,2020By Ilene Schneider

A Network Approach to Target Validation

Walter Kolch, co-founder and director of Systems Biology Ireland discusses the merits of a network approach to target validation and why probing clinical samples early is critical to increasing drug development success.

June23rd,2020

Webinar: Accelerating Patient-Derived Antibody Discovery and Optimization

Although antibody-based immunotherapies have greatly facilitated precision medicine in cancer, the increasingly smaller patient populations and challenging manufacture make them an expensive proposition. This webinar will highlight new approaches for accelerating antibody discovery and optimization.